Developer docs
API playgroundTry for free, no card

Search company profiles

BOOST Pharma

Full company profile

uuid000cy3q

Namestring
BOOST Pharma
Legal namestring
BOOST Pharma
Websiteurl
boostpharma.com
Company typeenum
Private
Founded yearint
2020
Descriptiontext

BOOST Pharma is a clinical-stage biopharmaceutical company developing BT-101, a first-in-class allogeneic mesenchymal stem cell (MSC) therapy for the treatment of Osteogenesis Imperfecta (OI), a rare genetic disorder also known as Brittle Bone Disease. The company was founded in 2019-2020 based on collaborative research from Karolinska Institutet in Stockholm, with headquarters at the Bio Innovation Institute in Copenhagen, Denmark. BT-101 is built on proprietary "BOOST Cells" that demonstrate higher calcium deposition, higher alkaline phosphatase activity, and high ectopic bone formation in preclinical models. Treatment involves four doses of allogeneic MSCs every fourth month, with the company specifically pursuing early intervention starting at prenatal diagnosis or as early as possible after birth to maximize therapeutic benefit for children with Type III and IV OI.

The company's lead clinical program, the BOOSTB4 Phase I/II multi-centre trial, has produced a strong efficacy signal: over 75% reduction in bone fracture rates at one year, approximately 78% reduction at two years, and over 50% of treated patients with zero fractures in the second year of follow-up. The product has been administered with a clean safety profile, with no adverse reactions or immune responses against donor MSCs. BOOST Pharma has secured Orphan Drug Designation in both the EU (December 2021) and the US (May 2022), as well as FDA Rare Paediatric Disease Designation (October 2022), positioning the program for market exclusivity and eligibility for a Priority Review Voucher upon marketing authorization. Following a successful FDA pre-IND meeting in November 2024, the company is preparing for a pivotal Phase III study in the US and Europe, with manufacturing being transferred to RoslinCT in Edinburgh for GMP production.

As a pre-revenue clinical-stage company, BOOST Pharma's commercial model relies on three planned revenue streams upon regulatory approval: (1) direct cell therapy product sales distributed through specialty pharmacies, hospital pharmacies, and rare pediatric treatment centers; (2) licensing or strategic partnership income from larger pharmaceutical companies for co-development or regional commercialization rights; and (3) potential monetization of the Priority Review Voucher from the Rare Paediatric Disease Designation. The customer base is narrow by design, focused on the estimated 56,000+ OI patients across the US and EU, with the company engaging regulatory authorities, clinical trial sites, and patient advocacy organizations such as OIFE. Leadership has been substantially upgraded in late 2025 and early 2026 with the appointments of CEO Hans Schambye (former Galecto Inc. CEO), Board Chair Elaine Jones (former Pfizer Ventures), and CRO Louise Himmelstrup to support Phase III execution and a future commercialization or partnership transaction.

Short descriptiontext

BOOST Pharma is a clinical-stage biopharmaceutical company developing BT-101, a first-in-class allogeneic mesenchymal stem cell therapy for children with Osteogenesis Imperfecta (Brittle Bone Disease), a rare genetic disorder with no approved disease-modifying treatments.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCopenhagen, Denmark
HQ citystring
Copenhagen
HQ countrystring
Denmark
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
stem cell therapy, rare disease biopharmaceuticals, allogeneic cell therapy, osteogenesis imperfecta treatment, mesenchymal stem cell products
Industry3 codes
PRIMARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAABAE
Stem Cell Therapies (MSC/iPSC/HSC-derived)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAIAIAN
Rare Pediatric & Congenital Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical and Medicine Manufacturing3254
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Rare Disease Biopharmaceuticals
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Cell Therapy Product Sales
TypeOne Time License
Description

Once BT-101 receives regulatory approval, the company plans to commercialize its cell therapy treatment for Osteogenesis Imperfecta through traditional pharmaceutical distribution channels, targeting hospitals and specialized treatment centers treating rare pediatric bone diseases.

regmednet.com
2Priority Review Voucher (PRV)
TypeLicensing Royalties
Description

The FDA's Rare Paediatric Disease (RPD) Designation allows BOOST Pharma to receive a priority review voucher upon marketing authorization, which can be sold to other pharmaceutical companies - representing a potential additional revenue stream.

boostpharma.com
3Strategic Partnerships and Licensing
TypeLicensing Royalties
Description

The company may pursue licensing agreements or strategic partnerships with larger pharmaceutical companies for co-development, commercialization rights, or regional partnerships for BT-101 distribution.

regmednet.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

BOOST Pharma is a clinical-stage biopharmaceutical company developing BT-101, an allogeneic mesenchymal stem cell (MSC) therapy using proprietary BOOST Cells that migrate to bone, engraft and form new bone tissue. The therapy targets Osteogenesis Imperfecta (Brittle Bone Disease), a rare genetic pediatric disorder, with treatment administered as four doses every fourth month beginning at prenatal diagnosis or as early as possible after birth.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Over 75% reduction in bone fracture rate observed in Phase I/II trial
+3 more records
Product overview1 text field

BOOST Pharma is a clinical-stage biopharmaceutical company developing a single lead product, BT-101, an off-the-shelf allogeneic mesenchymal stem cell therapy for Osteogenesis Imperfecta (OI). BT-101 is administered through the BOOSTB4 Phase I/II clinical trial and works by migrating to patient bones where cells engraft and initiate bone formation. Treatment can begin at the prenatal stage when OI is first diagnosed, or as early as possible after birth, targeting early intervention for maximum therapeutic benefit.

Product and service1 record
1BT-101 (BOOST Cells) allogeneic mesenchymal stem cell therapy
CategoryCell therapy / Rare disease biopharmaceuticals
Description

First-in-class allogeneic mesenchymal stem cell (MSC) therapy with high bone-forming capabilities for the treatment of Osteogenesis Imperfecta (OI / Brittle Bone Disease). Administered as four doses every fourth month, beginning at prenatal diagnosis or as early as possible after birth, with cells migrating to bone, engrafting and forming new bone tissue. Targets pediatric patients (Types III and IV OI) with no currently approved disease-modifying therapy.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-08
Description

Strategic manufacturing partnership between RoslinCT and BOOST Pharma to support Phase III development of BT-101, an allogeneic mesenchymal stem cell therapy for Osteogenesis Imperfecta. BOOST Pharma is transferring its manufacturing process to RoslinCT's Edinburgh facilities for GMP production.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

BOOST Pharma is based on collaborative research from Karolinska Institutet in Stockholm. Co-founder Dr. Cecilia Götherström is Associate Professor at Karolinska Institutet, and co-founder Professor Magnus Westgren is Senior Professor there. The company was established based on the research teams' work showing that BOOST cell treatment greatly enhanced quality of life for OI patients.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Gamida Cell develops cell therapies for hematologic malignancies and rare diseases. Similar to BOOST Pharma, they are a clinical-stage biotech with FDA-approved cell therapy products and use advanced cell manufacturing capabilities.

TypeBroad incumbent
Description

BioMarin is a major rare disease biopharmaceutical company. They are also developing therapies for OI and represent a broader incumbent with the resources to develop and commercialize rare disease therapies globally.

3Athersys
TypeDirect peer
Description

Athersys develops MultiStem, an allogeneic stem cell therapy platform for inflammatory, neurological, and cardiovascular conditions. Similar to BOOST Pharma, it focuses on off-the-shelf cell therapy products targeting diseases with significant unmet medical need.

TypeDirect peer
Description

Mesoblast develops allogeneic mesenchymal stem cell (MSC) therapies for inflammatory and degenerative diseases. Both companies leverage MSC technology platforms with proprietary manufacturing processes, serving as direct competitors in the allogeneic cell therapy space.

5TiGenix (acquired by Takeda)
TypeDirect peer
Description

TiGenix developed Cx601, an allogeneic MSC therapy for Crohn's disease that received EMA approval. As a pioneer in commercializing allogeneic MSC therapies, they represent a relevant benchmark for BOOST Pharma's regulatory and commercialization pathway.

TypeEmerging player
Description

Capricor develops cell-based therapies for Duchenne muscular dystrophy and other rare diseases. Both companies are clinical-stage biotechs developing innovative cell therapies for rare diseases with high unmet need.

TypeBroad incumbent
Description

Alexion is a leading rare disease biopharmaceutical company acquired by AstraZeneca. They have extensive experience commercializing high-priced orphan drugs and could be a potential acquirer or partner for BOOST Pharma's BT-101.

8Pluristem Therapeutics
TypeDirect peer
Description

Pluristem develops placenta-derived mesenchymal-like stem cell therapies. Both companies are clinical-stage biotechs focused on allogeneic cell therapies with proprietary manufacturing platforms and similar regulatory pathways.

TypeOthers
Description

RoslinCT is a contract development and manufacturing organization (CDMO) specializing in cell and gene therapies. They are BOOST Pharma's strategic manufacturing partner for Phase III and commercial supply of BT-101.

TypeBroad incumbent
Description

Ultragenyx is a rare disease biopharmaceutical company with setrusumab in development for Osteogenesis Imperfecta. While a broader rare disease player, they represent direct competition in the OI space with an alternative therapeutic approach.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BOOST Pharma

Rare Disease Biopharmaceuticalsboostpharma.com

BOOST Pharma is a clinical-stage biopharmaceutical company developing BT-101, a first-in-class allogeneic mesenchymal stem cell therapy for children with Osteogenesis Imperfecta (Brittle Bone Disease), a rare genetic disorder with no approved disease-modifying treatments.

What BOOST Pharma does

BOOST Pharma is a clinical-stage biopharmaceutical company developing BT-101, a first-in-class allogeneic mesenchymal stem cell (MSC) therapy for the treatment of Osteogenesis Imperfecta (OI), a rare genetic disorder also known as Brittle Bone Disease. The company was founded in 2019-2020 based on collaborative research from Karolinska Institutet in Stockholm, with headquarters at the Bio Innovation Institute in Copenhagen, Denmark. BT-101 is built on proprietary "BOOST Cells" that demonstrate higher calcium deposition, higher alkaline phosphatase activity, and high ectopic bone formation in preclinical models. Treatment involves four doses of allogeneic MSCs every fourth month, with the company specifically pursuing early intervention starting at prenatal diagnosis or as early as possible after birth to maximize therapeutic benefit for children with Type III and IV OI.

The company's lead clinical program, the BOOSTB4 Phase I/II multi-centre trial, has produced a strong efficacy signal: over 75% reduction in bone fracture rates at one year, approximately 78% reduction at two years, and over 50% of treated patients with zero fractures in the second year of follow-up. The product has been administered with a clean safety profile, with no adverse reactions or immune responses against donor MSCs. BOOST Pharma has secured Orphan Drug Designation in both the EU (December 2021) and the US (May 2022), as well as FDA Rare Paediatric Disease Designation (October 2022), positioning the program for market exclusivity and eligibility for a Priority Review Voucher upon marketing authorization. Following a successful FDA pre-IND meeting in November 2024, the company is preparing for a pivotal Phase III study in the US and Europe, with manufacturing being transferred to RoslinCT in Edinburgh for GMP production.

As a pre-revenue clinical-stage company, BOOST Pharma's commercial model relies on three planned revenue streams upon regulatory approval: (1) direct cell therapy product sales distributed through specialty pharmacies, hospital pharmacies, and rare pediatric treatment centers; (2) licensing or strategic partnership income from larger pharmaceutical companies for co-development or regional commercialization rights; and (3) potential monetization of the Priority Review Voucher from the Rare Paediatric Disease Designation. The customer base is narrow by design, focused on the estimated 56,000+ OI patients across the US and EU, with the company engaging regulatory authorities, clinical trial sites, and patient advocacy organizations such as OIFE. Leadership has been substantially upgraded in late 2025 and early 2026 with the appointments of CEO Hans Schambye (former Galecto Inc. CEO), Board Chair Elaine Jones (former Pfizer Ventures), and CRO Louise Himmelstrup to support Phase III execution and a future commercialization or partnership transaction.

BOOST Pharma firmographics

Firmographics
Name
BOOST Pharma
Legal name
BOOST Pharma
Website
https://boostpharma.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
11–50 employees
Short description
BOOST Pharma is a clinical-stage biopharmaceutical company developing BT-101, a first-in-class allogeneic mesenchymal stem cell therapy for children with Osteogenesis Imperfecta (Brittle Bone Disease), a rare genetic disorder with no approved disease-modifying treatments.
Ownership category
akta.pro rank

BOOST Pharma industry classification

Industry
Product category
Rare Disease Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAABAE
Stem Cell Therapies (MSC/iPSC/HSC-derived)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAIAIAN
Rare Pediatric & Congenital Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Stem cell therapy
  • Rare disease biopharmaceuticals
  • Allogeneic cell therapy
  • Osteogenesis imperfecta treatment
  • Mesenchymal stem cell products

Where BOOST Pharma is headquartered

Location

Headquarters

HQ city
Copenhagen
HQ country
Denmark
HQ region
Europe

Offices2 records

Markets served

BOOST Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

  1. Cell Therapy Product Sales: Once BT-101 receives regulatory approval, the company plans to commercialize its cell therapy treatment for Osteogenesis Imperfecta through traditional pharmaceutical distribution channels, targeting hospitals and specialized treatment centers treating rare pediatric bone diseases.
  2. Priority Review Voucher (PRV): The FDA's Rare Paediatric Disease (RPD) Designation allows BOOST Pharma to receive a priority review voucher upon marketing authorization, which can be sold to other pharmaceutical companies - representing a potential additional revenue stream.
  3. Strategic Partnerships and Licensing: The company may pursue licensing agreements or strategic partnerships with larger pharmaceutical companies for co-development, commercialization rights, or regional partnerships for BT-101 distribution.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

BOOST Pharma product offering

Product offering

Core offering

BOOST Pharma is a clinical-stage biopharmaceutical company developing BT-101, an allogeneic mesenchymal stem cell (MSC) therapy using proprietary BOOST Cells that migrate to bone, engraft and form new bone tissue. The therapy targets Osteogenesis Imperfecta (Brittle Bone Disease), a rare genetic pediatric disorder, with treatment administered as four doses every fourth month beginning at prenatal diagnosis or as early as possible after birth.

Product overview

BOOST Pharma is a clinical-stage biopharmaceutical company developing a single lead product, BT-101, an off-the-shelf allogeneic mesenchymal stem cell therapy for Osteogenesis Imperfecta (OI). BT-101 is administered through the BOOSTB4 Phase I/II clinical trial and works by migrating to patient bones where cells engraft and initiate bone formation. Treatment can begin at the prenatal stage when OI is first diagnosed, or as early as possible after birth, targeting early intervention for maximum therapeutic benefit.

Differentiator

Problem solved

Functional benefit

Products and services

  • BT-101 (BOOST Cells) allogeneic mesenchymal stem cell therapy First-in-class allogeneic mesenchymal stem cell (MSC) therapy with high bone-forming capabilities for the treatment of Osteogenesis Imperfecta (OI / Brittle Bone Disease). Administered as four doses every fourth month, beginning at prenatal diagnosis or as early as possible after birth, with cells migrating to bone, engrafting and forming new bone tissue. Targets pediatric patients (Types III and IV OI) with no currently approved disease-modifying therapy.

Quantifiable outcome

  • Over 75% reduction in bone fracture rate observed in Phase I/II trial
  • +3 more outcomes

Companies that use BOOST Pharma

Customer profile

Segments1 record

Ideal customer profiles2 records

BOOST Pharma technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

BOOST Pharma partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • RoslinCTcoreStrategic or Co-development Partner · 8 January 2026Strategic manufacturing partnership between RoslinCT and BOOST Pharma to support Phase III development of BT-101, an allogeneic mesenchymal stem cell therapy for Osteogenesis Imperfecta. BOOST Pharma is transferring its manufacturing process to RoslinCT's Edinburgh facilities for GMP production.
  • Karolinska InstitutetcoreStrategic or Co-development PartnerBOOST Pharma is based on collaborative research from Karolinska Institutet in Stockholm. Co-founder Dr. Cecilia Götherström is Associate Professor at Karolinska Institutet, and co-founder Professor Magnus Westgren is Senior Professor there. The company was established based on the research teams' work showing that BOOST cell treatment greatly enhanced quality of life for OI patients.

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

BOOST Pharma competitors and assessment

Company assessment

Emerging players

  • Gamida Cell: Gamida Cell develops cell therapies for hematologic malignancies and rare diseases. Similar to BOOST Pharma, they are a clinical-stage biotech with FDA-approved cell therapy products and use advanced cell manufacturing capabilities.
  • Capricor Therapeutics: Capricor develops cell-based therapies for Duchenne muscular dystrophy and other rare diseases. Both companies are clinical-stage biotechs developing innovative cell therapies for rare diseases with high unmet need.

Broad incumbents

  • BioMarin Pharmaceutical: BioMarin is a major rare disease biopharmaceutical company. They are also developing therapies for OI and represent a broader incumbent with the resources to develop and commercialize rare disease therapies globally.
  • Alexion (AstraZeneca Rare Disease): Alexion is a leading rare disease biopharmaceutical company acquired by AstraZeneca. They have extensive experience commercializing high-priced orphan drugs and could be a potential acquirer or partner for BOOST Pharma's BT-101.
  • Ultragenyx Pharmaceutical: Ultragenyx is a rare disease biopharmaceutical company with setrusumab in development for Osteogenesis Imperfecta. While a broader rare disease player, they represent direct competition in the OI space with an alternative therapeutic approach.

Direct peers

  • Athersys: Athersys develops MultiStem, an allogeneic stem cell therapy platform for inflammatory, neurological, and cardiovascular conditions. Similar to BOOST Pharma, it focuses on off-the-shelf cell therapy products targeting diseases with significant unmet medical need.
  • Mesoblast: Mesoblast develops allogeneic mesenchymal stem cell (MSC) therapies for inflammatory and degenerative diseases. Both companies leverage MSC technology platforms with proprietary manufacturing processes, serving as direct competitors in the allogeneic cell therapy space.
  • TiGenix (acquired by Takeda): TiGenix developed Cx601, an allogeneic MSC therapy for Crohn's disease that received EMA approval. As a pioneer in commercializing allogeneic MSC therapies, they represent a relevant benchmark for BOOST Pharma's regulatory and commercialization pathway.
  • Pluristem Therapeutics: Pluristem develops placenta-derived mesenchymal-like stem cell therapies. Both companies are clinical-stage biotechs focused on allogeneic cell therapies with proprietary manufacturing platforms and similar regulatory pathways.

Others

  • RoslinCT: RoslinCT is a contract development and manufacturing organization (CDMO) specializing in cell and gene therapies. They are BOOST Pharma's strategic manufacturing partner for Phase III and commercial supply of BT-101.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

BOOST Pharma social profiles

Digital presence

BOOST Pharma compliance and trust

Trust signal

Compliance3 records

BOOST Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BOOST Pharma leadership team

Management profile

Number of profiles

Profiles6 records

BOOST Pharma funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BOOST Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BOOST Pharma

What does BOOST Pharma do?

BOOST Pharma is a clinical-stage biopharmaceutical company developing BT-101, an allogeneic mesenchymal stem cell (MSC) therapy using proprietary BOOST Cells that migrate to bone, engraft and form new bone tissue. The therapy targets Osteogenesis Imperfecta (Brittle Bone Disease), a rare genetic pediatric disorder, with treatment administered as four doses every fourth month beginning at prenatal diagnosis or as early as possible after birth.

Is BOOST Pharma a public or private company?

BOOST Pharma is a private company. It is classified as venture growth investor backed and is currently operating.

When was BOOST Pharma founded?

BOOST Pharma was founded in 2020. It employs 11 to 50 people.

Where is BOOST Pharma based?

BOOST Pharma is headquartered in Copenhagen, Denmark, in the Europe region.

How does BOOST Pharma make money?

Three revenue lines are on record. Cell Therapy Product Sales are the primary driver. The others are priority Review Voucher (PRV) and strategic Partnerships and Licensing.

Who are BOOST Pharma's main competitors?

Emerging players on record are Gamida Cell and Capricor Therapeutics. Broad incumbents are BioMarin Pharmaceutical, Alexion (AstraZeneca Rare Disease) and Ultragenyx Pharmaceutical. Direct peers are Athersys, Mesoblast, TiGenix (acquired by Takeda) and Pluristem Therapeutics. RoslinCT is listed as an others.

Does BOOST Pharma have an API?

No public API is recorded for BOOST Pharma.

What industry is BOOST Pharma in?

BOOST Pharma's product category is Rare Disease Biopharmaceuticals. Its primary akta.pro industry code is HLAAAGAA, Stem Cell–Based Regenerative Therapies, with a secondary code of HLAAABAE, Stem Cell Therapies (MSC/iPSC/HSC-derived). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The future of tradingBOOST Pharma Selected to Showcase Phase III Ready Lead Program BT-101 at the 2026 Cell & Gene Meeting on the MesaBOOST Pharma will showcase its Phase III-ready BT-101 stem cell therapy at the 2026 Cell & Gene Meeting on the Mesa. The off-the-shelf treatment for osteogenesis imperfecta showed about 70% fracture reduction in a Phase I/II trial. The company plans a pivotal Phase III study.BioSpaceBOOST Pharma Selected to Showcase Phase III Ready Lead Program BT-101 at the 2026 Cell & Gene Meeting on the MesaBOOST Pharma will present its Phase III-ready BT-101 stem cell therapy at the 2026 Cell & Gene Meeting on the Mesa. The off-the-shelf therapy showed about 70% reduction in fractures in a Phase I/II trial, with no approved treatments for osteogenesis imperfecta.GlobeNewswireBOOST Pharma Appoints Leading Biopharma Leader Elaine Jones as ChairBOOST Pharma appointed Elaine Jones as Chair of its Board of Directors, succeeding Ingelise Saunders. The appointment supports the company's advancement of BT-101, a cell therapy for osteogenesis imperfecta, toward Phase III clinical development. The company will meet with partners and investors at spring industry events.GlobeNewswireBOOST Pharma Appoints Leading Biopharma Leader Elaine Jones as ChairBOOST Pharma, a clinical-stage biopharmaceutical company based in Stockholm, announced the appointment of Elaine Jones as Chair of its Board of Directors, succeeding Ingelise Saunders who will remain on the Board. Jones brings over two decades of life sciences experience, including roles at Pfizer Ventures and GSK's venture fund SR One, and currently serves on multiple biotech boards. The appointment coincides with BOOST Pharma's advancement of BT-101, its lead off-the-shelf cell therapy for osteogenesis imperfecta (Brittle Bone Disease), toward Phase III clinical trials, with early data showing promising reductions in fractures among affected children.YahooBOOST Pharma Appoints Leading Biopharma Leader Elaine Jones as ChairBOOST Pharma announced the appointment of Elaine Jones as Chair of its Board of Directors, succeeding Ingelise Saunders, as the company advances its lead therapy BT-101 toward Phase III clinical development. Jones brings more than two decades of life science experience, including senior roles at Pfizer Ventures and GSK's corporate venture fund. BT-101 is an off-the-shelf cell therapy for osteogenesis imperfecta (OI), a rare pediatric bone disorder with no currently approved disease-modifying treatments, and has received Orphan Drug Designation in both the U.S. and Europe.PharmiWeb.comBOOST Pharma Appoints Leading Biopharma Leader Elaine Jones as ChairBOOST Pharma, a clinical-stage biopharmaceutical company based in Stockholm, Sweden, announced the appointment of Elaine Jones as Chair of its Board of Directors, succeeding Ingelise Saunders who will remain on the Board. Jones brings over two decades of experience in the life sciences industry, including senior roles at Pfizer Ventures and GSK's corporate venture fund. The appointment is described as an important inflection point as BOOST Pharma advances BT-101, its lead off-the-shelf cell therapy for osteogenesis imperfecta (Brittle Bone Disease), toward Phase III clinical development.BioSpaceBOOST Pharma Appoints Leading Biopharma Leader Elaine Jones as ChairBOOST Pharma, a clinical-stage biopharmaceutical company based in Stockholm, announced the appointment of Elaine Jones as Chair of its Board of Directors, succeeding Ingelise Saunders who will remain on the Board. Jones brings over two decades of life science experience, including senior roles at Pfizer Ventures and GSK's corporate venture fund, and currently serves on multiple biotech boards. The appointment is intended to support the company's advancement of BT-101, its lead off-the-shelf cell therapy for osteogenesis imperfecta (Brittle Bone Disease), toward Phase III clinical development, following promising early trial data showing fracture reductions in affected children.GlobeNewswireHans Schambye Appointed as Chief Executive Officer of BOOST PharmaHans Schambye was appointed CEO of BOOST Pharma, effective immediately, advancing its lead candidate BT-101 for brittle bone disease. BT-101 showed >70% fracture reduction in year one and ~78% in year two, with Phase III trials planned for severe OI types.PharmiWeb.comHans Schambye Appointed as Chief Executive Officer of BOOST PharmaBOOST Pharma announced the appointment of Hans Schambye as its new Chief Executive Officer, effective immediately, with Schambye transitioning from his role on the company's Board of Directors. Schambye previously served as President and CEO of Galecto Inc., where he led the company through significant milestones and raised over $500 million in financing. The appointment comes as BOOST Pharma advances its lead candidate BT-101, a cell therapy for osteogenesis imperfecta (Brittle Bone Disease), toward Phase III trials after Phase I/II data showed a >70% reduction in fractures in year one and ~78% reduction by year two.Business InsiderHans Schambye Appointed as Chief Executive Officer of BOOST PharmaBOOST Pharma announced the appointment of Hans Schambye, MD, PhD, as its new Chief Executive Officer, effective immediately, with Schambye transitioning from the Board of Directors to lead the clinical-stage biopharmaceutical company full-time. Schambye joins from Galecto Inc., where he served as President and CEO and raised over $500 million, bringing extensive operational leadership and clinical development expertise. The appointment comes as BOOST Pharma advances its lead candidate BT-101 toward Phase III trials, with Phase I/II data showing a >70% reduction in fractures in year one and ~78% reduction by year two in patients with osteogenesis imperfecta (Brittle Bone Disease).